Orano Med
Dorine Prochasson is an experienced professional in the field of biotechnology and production, currently serving as a production technician and research and development technician at Orano Med since February 2021. Prior to this role, Dorine worked at Yposkesi as a process development technician for USP/DSP from October 2016 to February 2021, and held clinical research technician positions at Johnson & Johnson Health and Wellness Solutions, Inc. and Intertek in 2016. Additional experience includes a regulatory affairs assistant role at Cabinet d'Expert Toxicologue D. Sabouraud and a packaging operator position at Madrange from 2009 to 2014. Dorine's educational background includes specialized training in industrial bioproduction and biotechnology from IMT, a BTS in cosmetology, and a degree in English and Japanese from Université Bordeaux Montaigne.
This person is not in any offices
Orano Med
1 followers
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.